MURALI CHINTAGUMPALA to Bone Neoplasms
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about Bone Neoplasms.
Connection Strength
1.118
-
Risk-Based Therapy for Localized Osteosarcoma. Pediatr Blood Cancer. 2016 Mar; 63(3):412-7.
Score: 0.369
-
Targeted therapy in bone and soft tissue sarcoma in children and adolescents. Curr Oncol Rep. 2012 Apr; 14(2):197-205.
Score: 0.288
-
Integrated multimodal genetic testing of Ewing sarcoma--a single-institution experience. Hum Pathol. 2013 Oct; 44(10):2010-9.
Score: 0.078
-
Plasma proteome predicts chemotherapy response in osteosarcoma patients. Oncol Rep. 2011 Feb; 25(2):303-14.
Score: 0.066
-
Low-grade myofibroblastic sarcoma of the sacrum. J Neurosurg Pediatr. 2010 Sep; 6(3):286-90.
Score: 0.065
-
Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer. 2011 Jan 01; 117(1):207-17.
Score: 0.065
-
Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res. 2008 Jun; 6(6):937-46.
Score: 0.055
-
Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics. 2006 Jun; 6(11):3426-35.
Score: 0.048
-
Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005 Sep 15; 65(18):8142-50.
Score: 0.046
-
Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003 May 07; 95(9):669-74.
Score: 0.039